Your browser doesn't support javascript.
loading
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.
Martinez-Høyer, Sergio; Deng, Yu; Parker, Jeremy; Jiang, Jihong; Mo, Angela; Docking, T Roderick; Gharaee, Nadia; Li, Jenny; Umlandt, Patricia; Fuller, Megan; Jädersten, Martin; Kulasekararaj, Austin; Malcovati, Luca; List, Alan F; Hellström-Lindberg, Eva; Platzbecker, Uwe; Karsan, Aly.
Afiliación
  • Martinez-Høyer S; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Deng Y; Department of Hematology, Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Parker J; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Jiang J; Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Mo A; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Docking TR; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Gharaee N; Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Li J; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Umlandt P; Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Fuller M; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Jädersten M; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Kulasekararaj A; Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Malcovati L; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • List AF; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Hellström-Lindberg E; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
  • Platzbecker U; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Karsan A; Department of Haematological Medicine, King's College Hospital and King's College London, London, UK.
Nat Cell Biol ; 22(5): 526-533, 2020 05.
Article en En | MEDLINE | ID: mdl-32251398
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Cromosomas Humanos Par 5 / Megacariocitos / Diferenciación Celular / Lenalidomida Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Cell Biol Año: 2020 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Cromosomas Humanos Par 5 / Megacariocitos / Diferenciación Celular / Lenalidomida Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Nat Cell Biol Año: 2020 Tipo del documento: Article País de afiliación: Canadá